Evolus, Inc. (EOLS) Financials

EOLS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 220.6 million 249.4 million
Dec. 31, 2025 225.9 million 249.0 million
Sept. 30, 2025 219.0 million 247.8 million
June 30, 2025 228.8 million 247.5 million

EOLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -10.4 million 5.1 million
Dec. 31, 2025 11.3 million 5.1 million
Sept. 30, 2025 -16.8 million 5.1 million
June 30, 2025 -25.5 million 4.5 million

EOLS Net Income

No data available :(

EOLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 49.8 million 156.4 million 8.5 million
Dec. 31, 2025 53.8 million 146.1 million 8.9 million
Sept. 30, 2025 43.5 million 145.8 million 6.6 million
June 30, 2025 61.7 million 145.5 million 9.4 million

EOLS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 65.2 million
Dec. 31, 2025 64.5 million
Sept. 30, 2025 64.7 million
June 30, 2025 64.5 million

EOLS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 415000 2.2 million 52.0 million -
Dec. 31, 2025 1.5 million 3.5 million 54.7 million -
Sept. 30, 2025 2.2 million 2.0 million 52.8 million -
June 30, 2025 688000 1.8 million 56.7 million -

EOLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 73.1 million 25.8 million
Dec. 31, 2025 90.3 million 35.4 million
Sept. 30, 2025 69.0 million 23.1 million
June 30, 2025 69.4 million 24.1 million

EOLS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

EOLS

Price: $6.67

52 week price:
3.86
12.24

Earnings Per Share: -0.66 USD

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 16622

Market Capitalization: 418.8 million

Links: